Literature DB >> 22963908

Hepatitis C virus prevalence in The Netherlands: migrants account for most infections.

H J Vriend1, M G Van Veen, M Prins, A T Urbanus, H J Boot, E L M Op De Coul.   

Abstract

A population-based anti-hepatitis C virus (HCV) prevalence is important for surveillance purposes and it provides insight into the burden of disease. The outcomes of recent studies in the general Dutch population as well as recent HCV data from specific risk groups including migrants, men who have sex with men (MSM) and injecting drug users (IDUs), were implemented in a modified version of the Workbook Method (a spreadsheet originally designed for HIV estimations), to estimate Dutch HCV seroprevalence. The estimated national seroprevalence of HCV was 0·22% (min 0·07%, max 0·37%), corresponding to 28 100 (min n = 9600, max n = 48 000) HCV-infected individuals in The Netherlands. Of these, first-generation migrants from HCV-endemic countries (HCV prevalence ≥2%) accounted for the largest HCV-infected group, followed by IDUs and HIV-positive MSM.

Entities:  

Mesh:

Year:  2012        PMID: 22963908      PMCID: PMC9151883          DOI: 10.1017/S0950268812001884

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  22 in total

1.  An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales.

Authors:  D De Angelis; M Sweeting; Ae Ades; M Hickman; V Hope; M Ramsay
Journal:  Stat Methods Med Res       Date:  2008-11-26       Impact factor: 3.021

2.  Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections.

Authors: 
Journal:  AIDS       Date:  2002-06-14       Impact factor: 4.177

3.  Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission.

Authors:  Thijs J W van de Laar; Akke K van der Bij; Maria Prins; Sylvia M Bruisten; Kees Brinkman; Thomas A Ruys; Jan T M van der Meer; Henry J C de Vries; Jan-Willem Mulder; Michiel van Agtmael; Suzanne Jurriaans; Katja C Wolthers; Roel A Coutinho
Journal:  J Infect Dis       Date:  2007-06-11       Impact factor: 5.226

Review 4.  Surveillance and epidemiology of hepatitis B and C in Europe - a review.

Authors:  Merja Rantala; M J W van de Laar
Journal:  Euro Surveill       Date:  2008-05-22

Review 5.  The changing epidemiology of hepatitis C virus infection in Europe.

Authors:  Juan I Esteban; Silvia Sauleda; Josep Quer
Journal:  J Hepatol       Date:  2007-11-05       Impact factor: 25.083

6.  Modelling and calibration of the hepatitis C epidemic in Australia.

Authors:  K Razali; J Amin; G J Dore; M G Law
Journal:  Stat Methods Med Res       Date:  2008-11-26       Impact factor: 3.021

7.  Second national serum bank for population-based seroprevalence studies in the Netherlands.

Authors:  F R M van der Klis; L Mollema; G A M Berbers; H E de Melker; R A Coutinho
Journal:  Neth J Med       Date:  2009 Jul-Aug       Impact factor: 1.422

8.  Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004.

Authors:  G G G Baaten; G J B Sonder; N H T M Dukers; R A Coutinho; J A R Van den Hoek
Journal:  J Med Virol       Date:  2007-12       Impact factor: 2.327

9.  National estimate of HIV prevalence in the Netherlands: comparison and applicability of different estimation tools.

Authors:  Maaike G van Veen; Anne M Presanis; Stefano Conti; Maria Xiridou; Annemarie R Stengaard; Martin C Donoghoe; Ard I van Sighem; Marianne A van der Sande; Daniela De Angelis
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

10.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.

Authors:  Charlotte Van Den Berg; Colette Smit; Giel Van Brussel; Roel Coutinho; Maria Prins
Journal:  Addiction       Date:  2007-09       Impact factor: 6.526

View more
  16 in total

1.  The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.

Authors:  Adam Trickey; Hannah Fraser; Aaron G Lim; Amy Peacock; Samantha Colledge; Josephine G Walker; Janni Leung; Jason Grebely; Sarah Larney; Natasha K Martin; Matthew Hickman; Louisa Degenhardt; Margaret T May; Peter Vickerman
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

2.  Identification of hidden key hepatitis C populations: an evaluation of screening practices using mixed epidemiological methods.

Authors:  Angelique P A Vermeiren; Nicole H T M Dukers-Muijrers; Inge H M van Loo; Frans Stals; Dirk W van Dam; Ton Ambergen; Christian J P A Hoebe
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

3.  The Spatial Distribution of Hepatitis C Virus Infections and Associated Determinants--An Application of a Geographically Weighted Poisson Regression for Evidence-Based Screening Interventions in Hotspots.

Authors:  Boris Kauhl; Jeanne Heil; Christian J P A Hoebe; Jürgen Schweikart; Thomas Krafft; Nicole H T M Dukers-Muijrers
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

4.  Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?

Authors:  Anouk T Urbanus; Marjolijn van Keep; Amy A Matser; Mark H Rozenbaum; Christine J Weegink; Anneke van den Hoek; Maria Prins; Maarten J Postma
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

Review 5.  Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review.

Authors:  Freke R Zuure; Anouk T Urbanus; Miranda W Langendam; Charles W Helsper; Charlotte H S B van den Berg; Udi Davidovich; Maria Prins
Journal:  BMC Public Health       Date:  2014-01-22       Impact factor: 3.295

6.  Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial.

Authors:  Kirsty Roberts; John Macleod; Chris Metcalfe; Joanne Simon; Jeremy Horwood; William Hollingworth; Sharon Marlowe; Fiona H Gordon; Peter Muir; Barbara Coleman; Peter Vickerman; Graham I Harrison; Cherry-Ann Waldron; William Irving; Matthew Hickman
Journal:  Trials       Date:  2016-07-29       Impact factor: 2.279

Review 7.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

8.  Hepatitis C virus seroprevalence and prevalence of chronic infection in the adult population in Ireland: a study of residual sera, April 2014 to February 2016.

Authors:  Patricia Garvey; Brian O'Grady; Geraldine Franzoni; Maeve Bolger; Katie Irwin Crosby; Jeff Connell; Deirdre Burke; Cillian De Gascun; Lelia Thornton
Journal:  Euro Surveill       Date:  2017-07-27

9.  Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019).

Authors:  Ida Sperle; Stine Nielsen; Viviane Bremer; Martyna Gassowski; Henrikki Brummer-Korvenkontio; Roberto Bruni; Anna Rita Ciccaglione; Elena Kaneva; Kirsi Liitsola; Zlatina Naneva; Tanya Perchemlieva; Enea Spada; Salla E Toikkanen; Andrew J Amato-Gauci; Erika Duffell; Ruth Zimmermann
Journal:  Front Public Health       Date:  2021-05-28

10.  Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.

Authors:  Abby M Falla; Irene K Veldhuijzen; Amena A Ahmad; Miriam Levi; Jan Hendrik Richardus
Journal:  Eur J Public Health       Date:  2017-04-01       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.